Bearbmagovva

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta

Prostate cancer (PC) is the most common urogenital malignancy in older men and the second leading cause of death by cancer in men in Europe. Current therapeutic practice considers Androgen Deprivation Therapy (ADT) as first line treatment for clinically localized prostate cancer at high-risk, either...

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	Emilio Jesús Alegre del Rey (Dahkki), Rocío Asensi Díez (Dahkki), Juan Carlos García de Paredes Esteban (Dahkki)
Materiálatiipa:	Girji
Almmustuhtton:	Elsevier, 2017-07-01T00:00:00Z.
Fáttát:	article
Liŋkkat:	Connect to this object online.
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report
Dahkki: María Espinosa Bosch, et al.
Almmustuhtton: (2016)

Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis
Dahkki: Chun Xing Li, et al.
Almmustuhtton: (2024)

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer
Dahkki: Yang Chen, et al.
Almmustuhtton: (2022)

Farewell open letter to SEFH members
Dahkki: José Luis Poveda Andrés
Almmustuhtton: (2015)

The Stand of the SEFH Toward a Single Speciality
Dahkki: Olga Delgado-Sánchez, et al.
Almmustuhtton: (2020)

Expedición al conocimiento de una ciencia que reporta a la calidad de vida
Dahkki: BERTHA GONZÁLEZ FORTES

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
Dahkki: Ke Li, et al.
Almmustuhtton: (2019)

Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
Dahkki: Firas Almasri, et al.
Almmustuhtton: (2023)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
Dahkki: Tatenuma T, et al.
Almmustuhtton: (2023)

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Dahkki: Thiago S. Lima, et al.
Almmustuhtton: (2022)

Enfermedad premaligna y maligna en citologías reportas como ASCUS (Células escamosas atípicas de significado indeterminado)
Dahkki: Rodolfo León Casas Peña
Almmustuhtton: (1997)

Consensus SEO-SEFH of recommendations for use and compounding of ophthalmic preparations
Dahkki: Raquel Fuentes-Irigoyen, et al.
Almmustuhtton: (2018)

61th Congress of the SEFH. Top five clinical cases
Dahkki: Editor Jefe
Almmustuhtton: (2017)

61 SEFH Congress; Outstanding Clinical Cases (second part)
Dahkki: Editor Jefe
Almmustuhtton: (2017)

Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells
Dahkki: Xiao Wang, et al.
Almmustuhtton: (2022)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
Dahkki: Jukapun Yoodee, et al.
Almmustuhtton: (2022)

Preparation, Optimization, and In-Vitro Evaluation of Brusatol- and Docetaxel-Loaded Nanoparticles for the Treatment of Prostate Cancer
Dahkki: Tayo Alex Adekiya, et al.
Almmustuhtton: (2024)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
Dahkki: Huang Y, et al.
Almmustuhtton: (2022)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
Dahkki: Fakhri Rahman, et al.
Almmustuhtton: (2017)

Germline mutations of TP53 gene can be a key factor in prostate cancer genesis
Dahkki: Kawtar Aboulalaa, et al.
Almmustuhtton: (2024)

Genesis
Dahkki: Piper, H. Beam, 1904-1964

Genesis!
Dahkki: Winterbotham, R. R. (Russell Robert), 1904-1971; Morey, Leo, 1889-1965 [Illustrator]

RESULTS OF TREATMENT WITH GROWTH HORMONE IN A CHILD WITH STORTING OF MIXED GENESIS (CLINICAL CASE)
Dahkki: Наталья Александровна Жданова, et al.
Almmustuhtton: (2024)

Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors
Dahkki: Virginia Campani, et al.
Almmustuhtton: (2022)

Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH
Dahkki: Ruth Vera, et al.
Almmustuhtton: (2017)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
Dahkki: Peng-Fei Zhang, et al.
Almmustuhtton: (2021)

Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
Dahkki: Tengteng Jian, et al.
Almmustuhtton: (2022)

Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC)
Dahkki: Huan Xu, et al.
Almmustuhtton: (2022)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Dahkki: Joseph M. Unger, et al.
Almmustuhtton: (2018)

Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers
Dahkki: Meng Li, et al.
Almmustuhtton: (2019)

Genesis A
Dahkki: Cook, Albert S. (Albert Stanburrough), 1853-1927 [Editor]; Mason, Lawrence, 1882-1939 [Translator]

On the Genesis of Species
Dahkki: Mivart, St. George Jackson, 1827-1900

Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
Dahkki: Huina Wu, et al.
Almmustuhtton: (2024)

Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells
Dahkki: Laura Gallego-Yerga, et al.
Almmustuhtton: (2017)

Exosomal Circ-XIAP Promotes Docetaxel Resistance in Prostate Cancer by Regulating miR-1182/TPD52 Axis
Dahkki: Zhang H, et al.
Almmustuhtton: (2021)

circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3
Dahkki: Haoli Yin, et al.
Almmustuhtton: (2022)

Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems
Dahkki: Yipeng Xu, et al.
Almmustuhtton: (2022)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
Dahkki: N. K. Mazina, et al.
Almmustuhtton: (2017)

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
Dahkki: Li-Wen Chang, et al.
Almmustuhtton: (2021)

Píldora poscoital: un debate científico necesario
Dahkki: Emilio Jesús Alegre-del Rey, et al.
Almmustuhtton: (2016)